Equities

Alkem Laboratories Ltd

Alkem Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)5,583.35
  • Today's Change-23.40 / -0.42%
  • Shares traded108.56k
  • 1 Year change+22.98%
  • Beta0.6204
Data delayed at least 15 minutes, as of Nov 22 2024 10:19 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Alkem Laboratories Ltd. is an India-based pharmaceutical company with global operations, engaged in the development, manufacturing and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. It has a portfolio of more than 800 brands in India. The Company also has a presence in more than 40 international markets, with the United States being its key focus market. Its offerings include therapies, Rx products and Alkem generic. Its therapy offerings include anti-infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology and urology. Its product portfolio also includes mega-brands such as Clavam, Pan, Pan-D, and Taxim-O. Under the Alkem Generics cluster there are four divisions: Futura, Maxxio, Novokem and Alkem Healthcare.

  • Revenue in INR (TTM)127.06bn
  • Net income in INR21.22bn
  • Incorporated1973
  • Employees17.28k
  • Location
    Alkem Laboratories LtdAlmac House, Senapati Bapat MargMUMBAI 400013IndiaIND
  • Phone+91 2 239829999
  • Fax+91 2 224927190
  • Websitehttps://www.alkemlabs.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ALKEM:NSI since
announced
Transaction
value
Novartis India LtdPrior rumour discounted26 Sep 202426 Sep 2024Prior rumour discounted-10.38%--
Data delayed at least 15 minutes, as of Nov 22 2024 10:19 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ajanta Pharma Ltd44.91bn8.75bn367.93bn7.84k42.3510.0136.368.1969.5569.55356.94294.360.97381.334.165,725,128.0018.9716.6123.2920.4775.7773.2219.4819.312.1349.880.008831.2012.4515.4138.8116.10-14.9710.76
IPCA Laboratories Ltd85.33bn6.61bn399.22bn17.34k60.375.9637.424.6826.0726.07336.37264.100.74831.124.784,922,642.005.8810.339.0013.5267.3659.167.8512.251.3225.330.12912.8623.3915.3516.134.2417.9021.67
GlaxoSmithKline Pharmaceuticals Limited35.60bn6.75bn401.43bn3.21k59.8424.0053.9911.2739.6039.60209.3198.741.012.5914.8511,088,370.0019.2411.0136.0917.8861.7055.7718.9612.251.38554.800.0088192.076.212.00-2.915.78-36.029.86
Glenmark Pharmaceuticals Ltd122.48bn-10.18bn413.80bn14.99k--4.90--3.38-36.13-31.05434.11299.290.69511.534.048,171,082.00-5.641.02-8.511.4365.6459.47-8.111.431.002.560.174156.981.983.67-1,018.93---5.894.56
Abbott India Ltd60.66bn12.85bn576.17bn3.81k44.8516.3642.479.50604.57604.572,854.721,657.051.275.3215.7115,904,690.0026.8220.9236.9728.5945.0944.2021.1817.261.71131.360.016977.069.359.7226.5221.6831.0852.32
Alkem Laboratories Ltd127.06bn21.22bn670.13bn17.28k31.575.8327.095.27177.51177.511,062.75961.220.79311.725.147,354,390.0013.4911.8818.6617.5063.1059.2617.0113.941.9712.210.110429.829.2111.4882.4718.75-13.3020.11
Aurobindo Pharma Ltd302.95bn35.82bn708.58bn8.80k19.912.2913.852.3461.2961.29518.43531.650.65851.276.0434,437,900.007.799.2411.0813.4358.7653.3011.8312.721.1013.690.21448.6416.688.1964.626.0617.9612.47
Lupin Ltd214.31bn26.26bn932.01bn21.87k35.585.9625.404.3557.4257.42468.54342.910.87611.354.489,800,284.0010.841.4316.642.2268.6058.5212.372.041.2211.880.179775.0320.256.41345.1530.18-1.179.86
Zydus Lifesciences Ltd214.84bn42.78bn949.94bn26.24k22.264.3518.454.4242.4142.66212.94216.890.74951.755.018,187,310.0015.009.0519.9614.0171.4361.1520.0114.331.58217.940.007816.4813.408.2395.2515.72-3.03-3.04
Dr Reddy's Laboratories Ltd300.85bn53.39bn995.78bn26.34k18.673.2414.343.3164.0364.03360.85369.120.73791.373.9011,420,450.0013.3111.3718.1416.0270.6965.8618.0314.631.3630.690.134915.9113.5412.6423.7523.3926.7814.87
Data as of Nov 22 2024. Currency figures normalised to Alkem Laboratories Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

15.19%Per cent of shares held by top holders
HolderShares% Held
ICICI Prudential Asset Management Co. Ltd.as of 31 Oct 20243.88m3.24%
SBI Funds Management Ltd.as of 31 Oct 20242.35m1.96%
DSP Asset Managers Pvt. Ltd.as of 31 Oct 20242.03m1.70%
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Oct 20241.89m1.58%
The Vanguard Group, Inc.as of 06 Nov 20241.89m1.58%
HDFC Life Insurance Co. Ltd. (Investment Portfolio)as of 30 Jun 20241.73m1.45%
Norges Bank Investment Managementas of 30 Jun 20241.28m1.07%
Kotak Mahindra Asset Management Co. Ltd.as of 31 Oct 20241.23m1.03%
Kotak Mahindra Asset Management (Singapore) Pte Ltd.as of 30 Jun 2023974.21k0.82%
Axis Asset Management Co. Ltd.as of 31 Oct 2024905.50k0.76%
More ▼
Data from 30 Jun 2024 - 14 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.